Search Results

You are looking at 81 - 90 of 159 items for :

  • "BRAF mutation" x
  • Refine by Access: All x
Clear All
Full access

Presenter: Genevieve Boland

lymph nodes,” Dr. Boland said. Patients need to be tested for BRAF mutation status, staged appropriately, and surgically managed (wide excision, LND), with consideration given to enrolling appropriate patients in neoadjuvant trials. Adjuvant

Full access

NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Featured Updates to the NCCN Guidelines

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, and Lisa A. Gurski

5% to 9% of CRCs are characterized by a specific mutation in the BRAF gene (V600E). 32 , 33 BRAF mutations are, for all practical purposes, limited to tumors that do not have KRAS exon 2 mutations. 32 – 34 The NCCN panel currently recommends

Full access

Tatjana Gavrancic and Yeun-Hee Anna Park

molecularly selective settings. The targeting of the RAS/RAF/MEK/ERK pathway with clinically available surrogate markers harboring KRAS and/or BRAF mutations could be a strategy for selecting more responsive personalized cancer therapy using molecular

Full access

Scott Ramsey and Veena Shankaran

overall survival according to tumor KRAS and BRAF mutation status . J Clin Oncol 2011 ; 29 : 2011 – 2019 . 10 Douillard JY Siena S Cassidy J . Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and

Full access

John A. Thompson

trial, 675 patients with metastatic melanoma and BRAF mutation (as detected with the COBAS 4800 V600E mutation test) were randomized to vemurafenib (960 mg orally, twice daily) versus dacarbazine (1000 mg/kg every 3 weeks). 12 The hazard ratio for

Full access

Joshua B. Brown, Reetesh K. Pai, Melissa A. Burgess, Jennifer Chennat, and Amer H. Zureikat

KIT gene are the most common, accounting for 80% to 85% of GIST mutations, with PDGFR α mutations representing 5% to 10% of mutations. The remaining mutations have been termed wild-type ; however, SDH and BRAF mutations have been identified

Full access

Patrick M. Lynch

from epigenetic hypermethylation of the hMLH1 promoter, and also typically showing BRAF mutation) are worth detecting because of differences in prognosis and response to adjuvant therapies that include 5-FU. 14 This is the position of the EGAPP. 15

Full access

Jeremy Matloff, Aimee Lucas, Alexandros D. Polydorides, and Steven H. Itzkowitz

hypermethylation, whereas absence of the BRAF mutation suggests a germline mutation in MLH1, and thus LS. Depending on the population and study design, the percentage of carcinomas that show loss of DNA MMR protein expression is approximately 15% (and reported

Full access

Patrick M. Lynch

cases, an assay directed at detecting MLH-1 hypermethylation or its surrogate, BRAF mutation, may suggest the non-HNPCC/LS basis and a recommendation for no further HNPCC/LS-related testing. MSI/IHC testing is now often routine and does not require

Full access

Helena A. Yu and Gregory J. Riely

and acquired BRAF mutations as potential mechanisms of resistance, both of which have potential therapeutic implications that will require further study. 23 , 24 Second-Generation EGFR TKIs Acquired resistance to first-generation EGFR TKIs